- Genuine differentiation. Precision actives that target the biology of healthy aging at the species level — where everything else on the shelf is a commodity.
- Claims your regulatory and claims teams will accept. The substantiation a serious active requires — a clear mechanism, a Self-Affirmed GRAS pathway, and an evidence program that deepens over time — so your team signs off instead of pushing back.
- Formulation-friendly. Milligram-scale doses, shelf-stable, no cold chain — drop into capsules, sticks, beverages, powders, bars, and foods.
- A category story to sell. "Precision bioactives for healthy aging" gives your brand a narrative, not just an ingredient.
- IP-protected. You're building on something a competitor can't simply copy (see /ip).
What you get
- The ingredient — specified, food-grade, batch-released.
- The paperwork — CoA, specification sheet, TDS, and allergen statement for your QA.
- The science — mechanism and evidence documentation to support your claims team.
- A partner, not a vendor — pure-play B2B, so we never compete with you downstream.
The line today
- TRI-04 · gut barrier fiber, first US product 2027. Read →
- TRI-01 · gut–brain precision active. Read →
- Pipeline — nutraceutical and cosmeceutical actives in development. Read →
Proof
7 signed LOIs, including a top-4 global ingredient company. Process optimized with Bühler. Our ingredient is inside products at MISTA Demo Day, San Francisco, October 2026. Partners engage candidates before launch and shape formats, doses and claims.
From interest to supply
Engagement is staged, so you can commit at the pace your category requires: 1. Letter of intent — align on the active, target application, and volumes. 2. Evaluation — samples, specifications, and the evidence pack for your formulation and claims review. 3. GRAS: each product clears self-affirmed GRAS; TRI-04 supplies first, in 2027. 4. Supply agreement — commercial terms, volumes, and delivery.